AMTI - Applied Molecular Transport Inc.
Close
0.263
-0.044 -16.692%
Share volume: 0
Last Updated: Tue 26 Dec 2023 10:00:00 PM CET
Pharmaceutical Preparation Manufacturing :
2.72%
PREVIOUS CLOSE
CHG
CHG%
$0.31
-0.04
-14.30%
Fundamental analysis
24%
Profitability
25%
Dept financing
5%
Liquidity
35%
Performance
25%
Performance
5 Days
-5.45%
1 Month
-9.09%
3 Months
11.11%
6 Months
-50.36%
1 Year
-84.92%
2 Year
-98.96%
Key data
Stock price
$0.26
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.21 - $2.09
52 WEEK CHANGE
-$0.84
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Tahir Mahmood
Region: US
Website: appliedmt.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing
Region: US
Website: appliedmt.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing
Applied Molecular Transport Inc. engages in the design and development of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis.
Recent news